Restless Leg Syndrome Market Report 2026

The restless leg syndrome market size has grown rapidly in recent years. It will grow from $2.16 billion in 2025 to $2.45 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to increasing diagnosis of neurological disorders, rising prevalence of iron deficiency conditions, growing awareness of sleep-related health issues, expansion of neurology specialty clinics, improved access to oral medications.

The restless leg syndrome market size is expected to see rapid growth in the next few years. It will grow to $4.01 billion in 2030 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to increasing focus on personalized neurological therapies, rising demand for long-term symptom management solutions, expansion of digital sleep health tools, growing research into non-dopaminergic treatments, increasing patient awareness and diagnosis rates. Major trends in the forecast period include increasing use of dopamine modulating therapies, growing adoption of non-pharmacological treatment approaches, rising focus on sleep disorder management, expansion of personalized treatment strategies, enhanced awareness of secondary rls causes.

The growing prevalence of iron deficiency is anticipated to drive the expansion of the restless leg syndrome (RLS) market in the coming years. Iron deficiency is a condition in which the body does not have adequate iron levels to produce sufficient healthy red blood cells, resulting in symptoms such as fatigue, weakness, and pallor. The rising occurrence of iron deficiency is linked to factors including inadequate dietary intake, chronic blood loss, malabsorption disorders, and increased iron requirements during periods such as pregnancy and growth. Treatment for restless leg syndrome often includes iron supplementation or dietary modifications, which help relieve uncomfortable sensations and urges in the legs while addressing the underlying iron deficiency by restoring iron stores, supporting red blood cell production, and improving neurological function. For example, in January 2025, according to NHS England, a UK-based government agency, there were 191,927 hospital admissions related to iron deficiency during the 2023-24 period, representing an 11% increase compared to 2022-23. Therefore, the increasing prevalence of iron deficiency is fueling the growth of the restless leg syndrome market.

Major companies operating in the restless leg syndrome (RLS) market are concentrating on the development of innovative treatment options, such as novel non-invasive therapies, to improve symptom control and enhance patient outcomes. Novel non-invasive therapies involve advanced medical approaches that do not require surgical procedures or skin penetration and instead utilize techniques such as electrical stimulation, light-based therapy, or external medical devices. For instance, in April 2023, Varco Leg Care, an India-based consumer health technology company, received De Novo approval from the US Food and Drug Administration (FDA) for its NTX100 Tonic Motor Activation (TOMAC) System. The NTX100 TOMAC System is designed to treat moderate to severe restless leg syndrome and improve sleep quality in patients who do not respond adequately to pharmacological treatments. The device works by delivering electrical stimulation to the peroneal nerves on both sides of the body, inducing sustained muscle activation compatible with sleep, which helps suppress RLS symptoms.

In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics plc for an undisclosed amount. Through this acquisition, Amgen aims to expand its presence in rare and inflammatory disease markets, drive revenue growth, and accelerate the development of innovative therapies while increasing patient access to advanced treatments. Horizon Therapeutics plc is an Ireland-based biotechnology company with involvement in therapies related to restless leg syndrome.

Major companies operating in the restless leg syndrome market are Pfizer Inc., Roche Holding AG, Merck And Co Inc., Novartis International AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Astellas Pharma Inc., UCB S.A., Kyowa Kirin Co Ltd., Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Mundipharma International Limited, Azurity Pharmaceuticals LLC, Otsuka Pharmaceutical Co Ltd., Horizon Therapeutics plc, Mylan N.V., Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., Hikma Pharmaceuticals plc, Almirall S.A.

Europe was the largest region in the restless leg syndrome market in 2025. North-America is expected to be the fastest-growing region in the forecast period. The regions covered in the restless leg syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the restless leg syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the restless leg syndrome market by increasing costs of imported pharmaceutical ingredients, neurological drugs, diagnostic equipment, and medical devices used in treatment and monitoring. Healthcare systems in North America and Europe are most affected due to reliance on imported generic and branded medications, while Asia-Pacific faces higher production costs for exported neurological drugs. These tariffs are contributing to higher treatment expenses and reimbursement pressures. However, they are also supporting domestic drug manufacturing, regional generic production, and improved supply chain resilience for neurological therapies.

The restless leg syndrome market research report is one of a series of new reports that provides restless leg syndrome market statistics, including restless leg syndrome industry global market size, regional shares, competitors with a restless leg syndrome market share, detailed restless leg syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the restless leg syndrome industry. This restless leg syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Restless leg syndrome is a neurological disorder marked by an uncontrollable urge to move the legs, usually caused by uncomfortable or unpleasant sensations. Treatment options include lifestyle modifications, iron supplementation, medications that influence dopamine levels, and measures to improve sleep hygiene.

The main types of restless leg syndrome include primary restless leg syndrome and secondary restless leg syndrome. Primary restless leg syndrome occurs when symptoms arise without any underlying medical condition. Treatment approaches include medications, devices, and surgical options. These treatments are administered through various routes such as oral and injectable methods. They are distributed through channels including hospital pharmacies, retail pharmacies, and online pharmacies, and are applied in areas such as neurological treatment, sleep disorders, movement disorders, and symptom management.

The restless leg syndrome market consists of sales of benzodiazepines, sleep aids, transdermal patches, non-pharmacological therapies, and lifestyle management tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.